SEATTLE--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight-threatening eye diseases, today announced that it has achieved 50% subject enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat hydrochloride in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). The Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride (the SEATTLE) study is a multicenter, randomized, double-masked, dose-ranging study initiated earlier this year (ClinicalTrials.gov identifier: NCT01802866). A total of approximately 440 patients with GA associated with dry AMD are expected to be enrolled in the study across 56 sites, primarily in the United States. Emixustat hydrochloride is being studied to determine whether it slows the progression of GA lesions in these patients.
Help employers find you! Check out all the jobs and post your resume.
